Camostat is undergoing clinical trials for the treatment of COVID-19 with one with the Identifier NCT04608266 now in Phase III “A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection—COVID-19 in Ambulatory Adult Patients (CAMOVID).” Worthy of note is that because TMPRSS2 and furin are important for a variety of cellular processes in the host the risk of side effects may be heightened with the chronic use of inhibitors of these enzymes. This evidence concerns the gene TMPRSS2 and COVID-19.